To include your compound in the COVID-19 Resource Center, submit it here.

FDA extends review of Progenics' Azedra

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) slipped $0.82 (10%) to $7.54

Read the full 96 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE